Therapeutic Solutions International announced plans to initiate ten patient proof-of-concept clinical trial aimed at demonstrating the ability of FloraStilbene to stimulate the immune system in advanced breast cancer patients. The Company has previously been granted a patent on utilization of pterostilbene and pterostilbene compositions for synergy with cancer immunotherapy such as interleukin-2, as well as suppression of cancer derived immune inhibitory agent enzymes such as indolamine 2,3 dioxygenase. By combining previous experiences with immune modulation, the Company announced the creation of a novel immune stimulatory adjuvant combining pterostilbene with RU-486, termed "FloraStilbene".

Preclinical data, for which intellectual property has been filed, demonstrated immune suppression induced in the 4T1 mouse model of triple negative breast cancer.